Key result
Dabigatran linked to ~50% lower odds of ischemic stroke or TIA vs no OAC in AF.
Why the study?
Dabigatran is widely used for stroke prevention in AF, but concerns remain regarding its effectiveness in patients with Class III obesity.
Does dabigatran use reduce incident ischaemic stroke or transient ischaemic attack in patients with atrial fibrillation across different BMI categories?
Case-Control (n=1,854)
Yes
Does dabigatran use reduce incident ischaemic stroke or transient ischaemic attack in patients with atrial fibrillation across different BMI categories?
Dabigatran use is associated with a 50% reduction in the odds of ischemic stroke or TIA in patients with atrial fibrillation, with no significant effect modification by BMI, although efficacy in Class III obesity remains uncertain.
Answers are grounded in this paper and cite their sources.
Dabigatran was associated with lower IS/TIA odds across BMI; leaves open efficacy in class III obesity pending randomized data.
Dabigatran is widely used for stroke prevention in atrial fibrillation (AF), but concerns remain regarding its effectiveness in patients with Class III obesity ( BMI ≥40 kg/m2.) We evaluated the association between dabigatran use in patients with AF and ischaemic stroke (IS) or transient ischaemic attack (TIA) across body mass index (BMI) categories in a multiethnic New Zealand population. In this retrospective nested case–control study, cases with incident IS/TIA were identified from the fifth Auckland Regional Community Stroke Study (1st September 2020-31st August 2021), and event-free controls were randomly selected from the National Minimum Dataset. Multivariable logistic regression was used to estimate adjusted odds ratios (aORs) for IS/TIA, and effect modification by BMI catergory (< 30, 30–39.9, ≥40 kg/m 2 ) was assessed using an interaction term. Among 1,854 patients with AF (295 cases, 1,559 controls), dabigatran use was associated with lower odds of IS/TIA (adjusted odds ratio [aOR] 0.50, 95% CI 0.38–0.68). After multivariable adjustment, BMI was not independently associated with IS/TIA risk. The association between dabigatran use and lower IS/TIA risk was similar in patients with BMI <30 and 30–39.9 kg/m 2 , but the point estimate shifted towards the null in patients with BMI ≥40 kg/m 2 and was imprecise. There was no statistical evidence of effect modification by BMI (p-interaction=0.49), although clinically important attenuation in Class III obesity could not be excluded. In this real-world nested case–control study, there was no clear statistical evidence of BMI-related effect modification; however, the study had limited power in patients with BMI ≥40 kg/m 2 , and clinically important attenuation, including the possibility of no reduction in IS/TIA odds with dabigatran use in Class III obesity cannot be excluded. Graphical abstract Dabigatran use and cerebrovascular event risk across body mass index in atrial fibrillation. Graphical summary of the study design and main findings. In this real-world nested case–control study of patients with atrial fibrillation, dabigatran use was associated with lower odds of ischaemic stroke/transient ischaemic attack. There was no clear statistical evidence that BMI modified the association between dabigatran use and IS/TIA, although clinically important attenuation in Class III obesity could not be excluded.
No takes yet. Share an insight, caveat, or question.
Mahawish et al. (2026) conducted a case-control in Atrial fibrillation (n=1,854). Dabigatran vs. No oral anticoagulant was evaluated on Ischaemic stroke or transient ischaemic attack (IS/TIA) (aOR 0.50, 95% CI 0.38-0.68, p=<0.001). Dabigatran use was associated with a 50% lower odds of ischemic stroke or transient ischemic attack compared to no oral anticoagulant in patients with atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: